Nick Shubin, PhD serves as Program Director at Azure Biotech. Most recently, Dr. Shubin served as Chief Executive Officer of NemaGen Discoveries, a Rutgers-based biotechnology spin-out developing novel small-molecule inhibitors that block mast cell development from precursor cells. Under his leadership, the company advanced its program from target identification through the development of lead compounds ready for IND-enabling studies, with initial applications in systemic mastocytosis and longer-term potential in food allergy, asthma, and atopic dermatitis. As CEO, he led corporate strategy, fundraising, investor communications, and board governance, while building and guiding the company’s scientific and advisory infrastructure.

Dr. Shubin brings broad expertise in small-molecule drug development and biotech company building, including CRO selection and management, intellectual property strategy and execution (from provisional filings through national-phase PCTs), licensing agreement management, and clinical development planning. His experience also includes leading internal scientific teams, establishing and managing scientific advisory boards, directing successful grant-writing efforts, conducting market research, developing business plans, and providing regular updates to investors and boards of directors.

Dr. Shubin began his scientific career in Seattle, earning a BS in Cell and Molecular Biology from the University of Washington. He worked as a scientist at two biotechnology start-ups, Icogenex and Cardax Pharmaceuticals, before earning his PhD in Pathobiology from Brown University. He completed two postdoctoral fellowships at the University of Washington Department of Surgery at the University and at Seattle Children’s Research Institute.